Seres Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Seres Therapeutics, Inc. (MCRB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $351.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-05
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $351.00K.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $975.00K, a 86.50% decline year-over-year.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $3.44M, a 97.28% decline year-over-year.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $1.22M, a 76.90% decline year-over-year.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $7.13M, a 95.05% decline from fiscal 2021.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $143.86M, a 1109.19% increase from fiscal 2020.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $11.90M, a 56.24% decline from fiscal 2019.
- Seres Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $27.19M, a 1.01% increase from fiscal 2018.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $351.00K 10-Q · filed 2025-11-05 | |||||
| 2022-12-31 | $975.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.42M derived: sum of 2 quarters · filed 2023-03-07 | $5.63M derived: sum of 3 quarters · filed 2023-03-07 | $7.13M 10-K · filed 2023-03-07 | ||
| 2022-09-30 | $3.44M 10-Q · filed 2022-11-02 | $4.66M derived: sum of 2 quarters · filed 2022-11-02 | $6.15M 10-Q · filed 2022-11-02 | $13.37M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2022-06-30 | $1.22M 10-Q · filed 2022-08-03 | $2.71M 10-Q · filed 2022-08-03 | $9.93M derived: sum of 3 quarters · filed 2023-03-07 | $136.66M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2022-03-31 | $1.49M 10-Q · filed 2022-05-04 | $8.71M derived: sum of 2 quarters · filed 2023-03-07 | $135.44M derived: sum of 3 quarters · filed 2023-03-07 | $140.70M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $133.95M derived: sum of 2 quarters · filed 2023-03-07 | $139.21M derived: sum of 3 quarters · filed 2023-03-07 | $143.86M 10-K · filed 2023-03-07 | ||
| 2021-09-30 | $126.72M 10-Q · filed 2022-11-02 | $131.99M derived: sum of 2 quarters · filed 2022-11-02 | $136.64M 10-Q · filed 2022-11-02 | $137.81M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-06-30 | $5.26M 10-Q · filed 2022-08-03 | $9.91M 10-Q · filed 2022-08-03 | $11.08M derived: sum of 3 quarters · filed 2023-03-07 | $11.16M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-03-31 | $4.65M 10-Q · filed 2022-05-04 | $5.82M derived: sum of 2 quarters · filed 2023-03-07 | $5.90M derived: sum of 3 quarters · filed 2023-03-07 | $11.08M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $1.25M derived: sum of 2 quarters · filed 2023-03-07 | $6.43M derived: sum of 3 quarters · filed 2023-03-07 | $11.90M 10-K · filed 2023-03-07 | ||
| 2020-09-30 | $80.00K 10-Q · filed 2021-11-10 | $5.27M derived: sum of 2 quarters · filed 2021-11-10 | $10.73M 10-Q · filed 2021-11-10 | $16.01M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $5.19M 10-Q · filed 2021-08-03 | $10.65M 10-Q · filed 2021-08-03 | $15.93M derived: sum of 3 quarters · filed 2022-03-01 | $20.77M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $5.46M 10-Q · filed 2021-05-04 | $10.74M derived: sum of 2 quarters · filed 2022-03-01 | $15.58M derived: sum of 3 quarters · filed 2022-03-01 | $26.04M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.12M derived: sum of 2 quarters · filed 2022-03-01 | $20.57M derived: sum of 3 quarters · filed 2022-03-01 | $27.19M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $4.84M 10-Q · filed 2020-11-09 | $15.29M derived: sum of 2 quarters · filed 2020-11-09 | $21.91M 10-Q · filed 2020-11-09 | $32.10M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-06-30 | $10.45M 10-Q · filed 2020-07-28 | $17.07M 10-Q · filed 2020-07-28 | $27.27M derived: sum of 3 quarters · filed 2021-03-02 | $35.95M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-03-31 | $6.62M 10-Q · filed 2020-05-07 | $16.81M derived: sum of 2 quarters · filed 2021-03-02 | $25.50M derived: sum of 3 quarters · filed 2021-03-02 | $29.77M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2018-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $18.88M derived: sum of 2 quarters · filed 2021-03-02 | $23.15M derived: sum of 3 quarters · filed 2021-03-02 | $26.92M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $8.68M 10-Q · filed 2019-11-05 | $12.96M derived: sum of 2 quarters · filed 2019-11-05 | $16.72M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $4.27M 10-Q · filed 2019-08-06 | $4.61M 10-Q · filed 2018-08-02 | $8.04M 10-Q · filed 2019-08-06 | $8.58M 10-Q · filed 2018-08-02 | ||
| 2018-03-31 | $3.77M 10-Q · filed 2019-05-02 | |||||
| 2017-12-31 | $32.10M 10-K · filed 2020-03-02 | |||||
| 2017-06-30 | $3.01M 10-Q · filed 2018-08-02 | $6.03M 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | $21.77M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |